Kos Pharmaceuticals to Report Fourth Quarter and Full Year Results on February 23, 2006 Conference Call at 8:30 A.M. ET.CRANBURY, N.J. -- Kos Pharmaceuticals, Inc. (Nasdaq:KOSP), a fully integrated specialty pharmaceutical company, will announce results for the fourth quarter and full year ended December 31, 2005, before the market opens on Thursday, February 23, 2006. Following the release, Kos' senior management will host a conference call at 8:30 a.m. ET to discuss the Company's results. The conference call will be available live via the Internet by accessing Kos' website at www.kospharm.com. Please go to the website at least fifteen minutes prior to the call to register, download and install any necessary audio software. Those who cannot access the webcast can dial into the conference call at 913-981-5542 confirmation code 9534014. A replay will also be available on the website at www.kospharm.com or by calling 888-203-1112 domestic or international, and entering 9534014 from 2:00 PM ET on February 23, 2006 until 12:00 AM ET on February 27, 2006. If you would like to receive notices and news regarding Kos, please visit the Investor Relations Investor relations The process by which the corporation communicates with its investors. section of the Company website and subscribe to Verb 1. subscribe to - receive or obtain regularly; "We take the Times every day" subscribe, take buy, purchase - obtain by purchase; acquire by means of a financial transaction; "The family purchased a new car"; "The conglomerate acquired a new company"; email alerts. Kos Pharmaceuticals, Inc. is a fully integrated specialty pharmaceutical company engaged in developing, commercializing, manufacturing and marketing proprietary prescription products for the treatment of chronic diseases. The Company's principal product development strategy is to reformulate Verb 1. reformulate - formulate or develop again, of an improved theory or hypothesis redevelop formulate, explicate, develop - elaborate, as of theories and hypotheses; "Could you develop the ideas in your thesis" existing pharmaceutical products with large market potential to improve safety, efficacy, or patient compliance. The Company currently markets Niaspan(R) and Advicor(R) for the treatment of cholesterol disorders, Azmacort(R) for the treatment of asthma, Cardizem(R)LA for the treatment of hypertension and angina Angina Definition Angina is pain, "discomfort," or pressure localized in the chest that is caused by an insufficient supply of blood (ischemia) to the heart muscle. , Teveten(R) and Teveten(R)HCT Hct abbr. hematocrit HCT Hematocrit, see there for the treatment of hypertension. Kos is developing additional products, has proprietary drug delivery technologies in solid-dose and aerosol aerosol (âr`əsōl,–sŏl): see colloid. aerosol System of tiny liquid or solid particles evenly distributed in a finely divided state through a gas, usually air. metered-dose inhalation inhalation /in·ha·la·tion/ (in?hah-la´shun) 1. the drawing of air or other substances into the lungs.inhala´tional 2. the drawing of an aerosolized drug into the lungs with the breath. 3. administration and is pursuing certain strategic business development and licensing opportunities. |
|
||||||||||||||||
Printer friendly
Cite/link
Email
Feedback
Reader Opinion